CA2414352A1 - Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies - Google Patents
Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies Download PDFInfo
- Publication number
- CA2414352A1 CA2414352A1 CA002414352A CA2414352A CA2414352A1 CA 2414352 A1 CA2414352 A1 CA 2414352A1 CA 002414352 A CA002414352 A CA 002414352A CA 2414352 A CA2414352 A CA 2414352A CA 2414352 A1 CA2414352 A1 CA 2414352A1
- Authority
- CA
- Canada
- Prior art keywords
- treating
- neuropathies
- peripheral
- derivative
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 11
- 206010061666 Autonomic neuropathy Diseases 0.000 title claims abstract 4
- 208000018262 Peripheral vascular disease Diseases 0.000 title claims abstract 4
- 208000033808 peripheral neuropathy Diseases 0.000 title claims abstract 4
- 208000027232 peripheral nervous system disease Diseases 0.000 title claims abstract 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract 4
- 208000008960 Diabetic foot Diseases 0.000 claims abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims abstract 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims abstract 3
- 201000002829 CREST Syndrome Diseases 0.000 claims abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims abstract 2
- 229960003310 sildenafil Drugs 0.000 claims abstract 2
- 101150085511 PEDS1 gene Proteins 0.000 claims 5
- 102100037592 Plasmanylethanolamine desaturase Human genes 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 229920003199 poly(diethylsiloxane) Polymers 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 2
- 208000003790 Foot Ulcer Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A method of treating a patient suffering from peripheral vascular disease, peripheral neuropathies, or autonomic neuropathies by administering a cGMP
PDE5 inhibitor such as sildenafil. The method is particularly applicable to patients suffering from diabetic foot ulcers, Raynaud's Phenomenon, CREST
Syndrome, erythromatosis, rheumatoid diseases, diabetic retinopathies and onychiomycosis. According to the present invention, a cGMP PDE5 inhibitor may be administered as a prophylactic to patients predisposed to develop a peripheral vascular disease, peripheral neuropathy or autonomic neuropathy.
PDE5 inhibitor such as sildenafil. The method is particularly applicable to patients suffering from diabetic foot ulcers, Raynaud's Phenomenon, CREST
Syndrome, erythromatosis, rheumatoid diseases, diabetic retinopathies and onychiomycosis. According to the present invention, a cGMP PDE5 inhibitor may be administered as a prophylactic to patients predisposed to develop a peripheral vascular disease, peripheral neuropathy or autonomic neuropathy.
Description
METHOD
Claims (7)
1. A method of treating the disease of a type selected from peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies, comprising administering an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
2. A method of treating a disease according to claim 1 wherein said disease is selected from the group consisting of Raynaud's Phenomenon, CREST syndrome, erythromatosis, rheumatoid diseases and diabetic retinopathies.
3. A method of treating onychiomycosis comprising administering an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
4. A method of treating a patient suffering from diabetic foot ulcers which comprises treating said patient with an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
5. A method of preventing the formation of foot ulcers in a patient suffering from the disease diabetes, the method comprising administering to said patient an effective amount of a pharmaceutical composition comprising a cGMP PDES inhibitor or a derivative or salt thereof.
6. A method of manufacturing a diabetic foot ulcer therapeutic comprising providing an effective ingredient selected from the group consisting of a cGMP
PDES
inhibitor, a derivative thereof, and a salt thereof and combining said effective ingredient with a suitable carrier for administration to a patient.
PDES
inhibitor, a derivative thereof, and a salt thereof and combining said effective ingredient with a suitable carrier for administration to a patient.
7. A method according to claim 4 or 5, wherein the cGMP PDE 5 inhibitor is sildenafil.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21506500P | 2000-06-30 | 2000-06-30 | |
| US60/215,065 | 2000-06-30 | ||
| US21902900P | 2000-07-18 | 2000-07-18 | |
| US60/219,029 | 2000-07-18 | ||
| PCT/US2001/041202 WO2002002118A1 (en) | 2000-06-30 | 2001-06-29 | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2414352A1 true CA2414352A1 (en) | 2002-01-10 |
Family
ID=26909649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002414352A Abandoned CA2414352A1 (en) | 2000-06-30 | 2001-06-29 | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1303279A1 (en) |
| JP (1) | JP2004511433A (en) |
| KR (1) | KR20030047907A (en) |
| CN (1) | CN1440287A (en) |
| AU (1) | AU2001279275A1 (en) |
| BR (1) | BR0112100A (en) |
| CA (1) | CA2414352A1 (en) |
| HU (1) | HUP0301451A3 (en) |
| IL (1) | IL153426A0 (en) |
| MX (1) | MXPA03000033A (en) |
| NZ (1) | NZ523108A (en) |
| PL (1) | PL365565A1 (en) |
| WO (1) | WO2002002118A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020588D0 (en) * | 2000-08-21 | 2000-10-11 | Pfizer Ltd | Treatment of wounds |
| US8133903B2 (en) | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
| WO2004082667A1 (en) * | 2003-03-17 | 2004-09-30 | Pfizer Products Inc. | Treatment of type 1 diabetes with pde5 inhibitors |
| FR2877013A1 (en) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | INDENTIFICATION OF A JAK2 MUTATION INVOLVED IN THE VAQUEZ POLYGLOBULIA |
| US20090074796A1 (en) * | 2005-01-07 | 2009-03-19 | The John Hopkins University | Pde5 inhibitor compositions and methods for immunotherapy |
| MX2017016930A (en) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Method of treatment of diabetic foot ulcers. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6043252A (en) * | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
| US6075028A (en) * | 1999-09-23 | 2000-06-13 | Graham; Richard | Method of treating Tourette's syndrome and related CNS disorders |
-
2001
- 2001-06-29 WO PCT/US2001/041202 patent/WO2002002118A1/en not_active Ceased
- 2001-06-29 HU HU0301451A patent/HUP0301451A3/en unknown
- 2001-06-29 CN CN01812103A patent/CN1440287A/en active Pending
- 2001-06-29 BR BR0112100-6A patent/BR0112100A/en not_active IP Right Cessation
- 2001-06-29 MX MXPA03000033A patent/MXPA03000033A/en unknown
- 2001-06-29 PL PL01365565A patent/PL365565A1/en not_active Application Discontinuation
- 2001-06-29 EP EP01957540A patent/EP1303279A1/en not_active Withdrawn
- 2001-06-29 JP JP2002506740A patent/JP2004511433A/en active Pending
- 2001-06-29 NZ NZ523108A patent/NZ523108A/en unknown
- 2001-06-29 AU AU2001279275A patent/AU2001279275A1/en not_active Abandoned
- 2001-06-29 KR KR1020027017948A patent/KR20030047907A/en not_active Ceased
- 2001-06-29 IL IL15342601A patent/IL153426A0/en unknown
- 2001-06-29 CA CA002414352A patent/CA2414352A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002002118A1 (en) | 2002-01-10 |
| HUP0301451A3 (en) | 2004-10-28 |
| HUP0301451A2 (en) | 2003-09-29 |
| MXPA03000033A (en) | 2003-09-25 |
| PL365565A1 (en) | 2005-01-10 |
| NZ523108A (en) | 2005-04-29 |
| CN1440287A (en) | 2003-09-03 |
| AU2001279275A1 (en) | 2002-01-14 |
| IL153426A0 (en) | 2003-07-06 |
| BR0112100A (en) | 2003-05-20 |
| JP2004511433A (en) | 2004-04-15 |
| EP1303279A1 (en) | 2003-04-23 |
| KR20030047907A (en) | 2003-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532663A (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| JP2007514750A5 (en) | ||
| JP2004507496A5 (en) | ||
| KR20070032619A (en) | Combination Therapeutics of Iloprost for the Treatment of Pulmonary Hypertension | |
| RU2002127804A (en) | MEDICINAL SYSTEM FOR TREATMENT OF COMPLICATIONS CONNECTED WITH DIABETES AND NEUROPATHY, AND THEIR APPLICATION | |
| JP2002528502A5 (en) | ||
| JP2004537500A5 (en) | ||
| CA2414352A1 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
| JP2002534477A (en) | New use of melagatran | |
| JPH01261334A (en) | Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof | |
| CA2559239A1 (en) | Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| AU2002220960B2 (en) | Regeneration of blood vessels | |
| EP1033133A4 (en) | Composition for treatment of diabetes and treatment of diabetes | |
| AU2002220960A1 (en) | Regeneration of blood vessels | |
| CA2474703A1 (en) | Therapeutic agent of glaucoma comprising bunazosin and prostaglandins | |
| JP2001316293A5 (en) | ||
| SK12202002A3 (en) | Novel galenical form for oral administration with prolonged release of molsidomine | |
| RU2003106417A (en) | APPLICATION OF A VITAMIN COMBINATION FOR TREATMENT OF PRIMARY HEAD PAIN | |
| CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque | |
| MD1568G2 (en) | Method of treatment of the burn disease in the burn shock period | |
| Klemsdal et al. | A new isosorbide dinitrate extended-release formulation: pharmacokinetic and clinical parameters in patients with stable angina pectoris | |
| EP1264601A3 (en) | Treatment of a coronary condition by delivery of therapeutics to the pericardial space | |
| DE60202299D1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING SALMETEROL AND BUDESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| AU674376B2 (en) | 4-guanidinobutyramide for improving blood circulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |